Gamma hydroxybutyric acid granules
A granule including a solid core on which is supported an active ingredient, said active ingredient being selected from gamma-hydroxybutric acid or one of its pharmaceutically acceptable salts, said granule further including, supported on said solid core, one or more compounds which may generate gas evolvement, one or more diluents, said granule being in that it is coated with a membrane, and in that the solid core represents from 15% to 50% by weight based on the total weight of the granule.
1. A coated granule composed of a solid core on which is supported
an active ingredient, the active ingredient being selected from gamma hydroxybutric acid or one of its pharmaceutically acceptable salts,
a gas generator,
a diluent,
a binder, and
a coating membrane, where
the coating membrane is a layer surrounding the active ingredient, the gas generator, the diluent, and the binder, and the layer has a surface that is an outermost surface of the coated granule; wherein
the coated granule consists of the following, by weight based on the total weight of the granule:
15-25% of the solid core,
50-60% of the active ingredient,
5-15% of the gas generator,
2-18% of the diluent,
3-10% of the binder,
3-6% of the coating membrane;
the gas generator is sodium bicarbonate;
the diluent is magnesium aluminometasilicate; and
the binder is shellac.
2. The granule according to claim 1 , wherein the solid core is one or more member selected from the group consisting of polyols, gums, derivatives of silica, calcium derivatives, potassium derivatives, mineral compounds, dicalcium phosphates, tricalcium phosphates, calcium carbonates, saccharose, cellulose derivatives, microcrystalline cellulose, ethyl cellulose, hydroxypropylmethylcellulose, and starch.
3. The granule according to claim 1 , wherein the coating membrane consists of coating excipients for immediate release.
4. The granule according to claim 1 , wherein the coating membrane consists of coating excipients for sustained release.
5. The granule according to claim 1 , wherein
the magnesium aluminometasilicate is synthetic and amorphous.
6. A pharmaceutical composition comprising a mixture of granules including the coated granule according to claim 1 , wherein said mixture consists of two groups of granules having different kinetics for releasing the active ingredient.
7. A method for treating a pathology requiring at least very fast in vivo availability of GHB, the method comprising administering an effective amount of a composition comprising the coated granule of claim 1 to a patient to treat the pathology.
8. The method according to claim 7 , wherein the pathology is narcolepsy.
9. The method according to claim 7 , wherein the pathology is alcoholic withdrawal.
10. A pharmaceutical composition comprising:
at least one coated granule according to claim 1 , and
granules of a sweetener.